Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 27

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 27
---
.” The following table summarizes the shares issued and outstanding with respect to Awards granted under all of the Company's equity incentive plans (i.e., the 2018 Plan, the 2014 Employment Commencement Incentive Plan and the 2024 Employment Commencement Incentive Plan) as of March 31, 2025:

| Total number of stock options outstanding                               |     | As of 3/31/25 | 9,117,835 |
|:------------------------------------------------------------------------|:----|:--------------|----------:|
| Weighted-average exercise price per share of outstanding stock options  |     | $             |     80.27 |
| Weighted-average remaining term of outstanding stock options (in years) |     |               |       4.7 |
| Total number of full value awards outstanding (1)                       |     |               | 2,995,735 |
| Total number of shares available for grant under Company equity plans   |     |               | 2,092,367 |

(1) Reflects a total number of 2,829,697 shares underlying outstanding RSUs and 166,038 shares underlying outstanding PSUs. As of March 31, 2025, approximately 1,371 of our employees, officers and directors were eligible to participate in the 2018 Plan, of which six were executive officers (and of which five were named executive officers), 1,357 were non-executive employees, and eight were non-employee directors. As of March 31, 2025, none of our consultants were eligible to participate in the 2018 Plan. It is important for the Company to obtain the additional shares requested for the share reserve under the 2018 Plan because the Board believes the current number of shares available for awards under the 2018 Plan is not sufficient for the Company to provide equity incentives to eligible employees, and other eligible service providers over the next year, which could inhibit the quality of employees and service providers that the Company is able to attract, motivate and retain. If our stockholders do not approve the amendment to the 2018 Plan, which increases the share reserve under the 2018 Plan, the 2018 Plan will remain in effect; however, we believe that the shares currently available for issuance under this plan will be quickly depleted, and we will lose our ability to use equity as a compensation and incentive tool to retain key talent and instead will have to increase the use of cash-based awards to incentivize, motivate